Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception.
The study examined the effect of pretreatment counseling upon discontinuation of 150 mg depo-medroxyprogesterone acetate (Depo-Provera (DMPA)), given for contraception. A total of 421 Chinese women participated, 204 receiving detailed structured pretreatment and ongoing counseling on the hormonal effects and probable side effects of DMPA and 217 receiving only routine counseling. The primary study endpoint was termination rate; secondary endpoints were frequency of medical events and reasons for termination. Study termination rates were significantly lower in the intensive structured counseling group than in the routine counseling group. At one year, the total cumulative termination rates were 11% (23/204) and 42% (92/217), respectively (p < 0.0001). The most common reasons for terminating DMPA were menstrual changes. No pregnancy, serious or unexpected medical events were reported, nor were statistically or clinically significant changes in vital signs observed. We conclude that pretreatment counseling on expected side effects increases the acceptability of DMPA.
Lei
Z W
ZW
Sichuan Reproductive Health Institute, Chengdu, PR China.
Wu
S C
SC
Garceau
R J
RJ
Jiang
S
S
Yang
Q Z
QZ
Wang
W L
WL
Vander Meulen
T C
TC
D000293:Adolescent; D000328:Adult; D000568:Amenorrhea / Q000139:chemically induced; D001835:Body Weight; D001942:Breast Feeding; D002681:China / Q000453:epidemiology; D003267:Contraception / Q000706:statistics & numerical data*; D003271:Contraceptive Agents, Female / Q000009:adverse effects / Q000627:therapeutic use*; D003376:Counseling / Q000379:methods*; D005260:Female; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000009:adverse effects / Q000627:therapeutic use*; D008599:Menstruation Disturbances / Q000139:chemically induced; D010349:Patient Compliance; D010352:Patient Dropouts / Q000706:statistics & numerical data*; D018579:Patient Selection; D011247:Pregnancy; D045167:Progesterone Congeners / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D003271:Contraceptive Agents, Female; D045167:Progesterone Congeners; D017258:Medroxyprogesterone Acetate